5/8
07:25 am
athe
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Medium
Report
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
4/30
07:42 am
athe
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report [Yahoo! Finance]
Medium
Report
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report [Yahoo! Finance]
4/30
07:25 am
athe
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Medium
Report
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
4/29
07:29 am
athe
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia [Yahoo! Finance]
High
Report
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia [Yahoo! Finance]
4/29
07:25 am
athe
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
High
Report
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
4/17
07:33 am
athe
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
4/17
07:30 am
athe
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]
4/17
07:25 am
athe
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Low
Report
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
4/10
07:32 am
athe
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 [Financial Post (Toronto, Ontario, Canada)]
High
Report
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 [Financial Post (Toronto, Ontario, Canada)]
4/10
07:25 am
athe
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
High
Report
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
3/26
10:25 am
athe
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Low
Report
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
3/7
08:50 am
athe
Alterity Therapeutics Limited (NASDAQ: ATHE) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $4.00 price target on the stock.
Low
Report
Alterity Therapeutics Limited (NASDAQ: ATHE) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $4.00 price target on the stock.
2/20
10:38 am
athe
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
2/20
10:25 am
athe
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
Low
Report
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting